Wiesweg, Marcel
Kasper, Stefan
Worm, Karl
Herold, Thomas
Reis, Henning
Sara, Linda
Metzenmacher, Martin
Abendroth, Annalena
Darwiche, Kaid
Aigner, Clemens
Wedemeyer, Heiner H.
Helfritz, Fabian A.
Stuschke, Martin
Schumacher, Brigitte
Markus, Peter
Paul, Andreas
Rahmann, Sven
Schmid, Kurt W.
Schuler, Martin
Funding for this research was provided by:
Deutsche Krebshilfe (110534)
the German Federal and State governments via the German Cancer Consortium
Medical Faculty of the University Duisburg-Essen
Article History
Received: 11 June 2018
Revised: 21 September 2018
Accepted: 21 November 2018
First Online: 19 December 2018
Compliance with ethical standards
:
: We declare the following potential conflicts of interest: Prof. Dr. M. Schuler: Consultancy: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), Lilly, Novartis; Honoraria for CME presentations: Alexion, Boehringer Ingelheim, Celgene, GlaxoSmithKline, Lilly, Novartis; Research funding to institution: Boehringer Ingelheim, Bristol Myers-Squibb, Novartis; Other: Universität Duisburg-Essen (Patents). Prof. Dr. S. Kasper: Consultancy, Honoraria and Travel Support: Roche, Bristol-Myers Squibb, Merck Sharp & Dohme. All remaining authors declare that they have no conflict of interest.